Paul Mathew

3.5k total citations
96 papers, 2.4k citations indexed

About

Paul Mathew is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Paul Mathew has authored 96 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Pulmonary and Respiratory Medicine, 40 papers in Oncology and 18 papers in Molecular Biology. Recurrent topics in Paul Mathew's work include Prostate Cancer Treatment and Research (55 papers), Bone health and treatments (18 papers) and Radiopharmaceutical Chemistry and Applications (12 papers). Paul Mathew is often cited by papers focused on Prostate Cancer Treatment and Research (55 papers), Bone health and treatments (18 papers) and Radiopharmaceutical Chemistry and Applications (12 papers). Paul Mathew collaborates with scholars based in United States, Spain and Brazil. Paul Mathew's co-authors include Christopher J. Logothetis, Isaiah J. Fidler, Patricia Troncoso, Liping Wang, Xiufeng Pang, Peter F. Thall, Lance C. Pagliaro, Nizar M. Tannir, Hisanori Uehara and C. Logothetis and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Paul Mathew

92 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paul Mathew United States 26 1.3k 857 749 479 361 96 2.4k
Teng Ma China 26 461 0.4× 487 0.6× 1.2k 1.6× 452 0.9× 303 0.8× 98 2.3k
Alfredo Addeo Switzerland 34 1.6k 1.2× 2.2k 2.6× 860 1.1× 550 1.1× 222 0.6× 191 3.5k
Yucai Wang United States 27 430 0.3× 1.5k 1.7× 614 0.8× 259 0.5× 126 0.3× 197 3.0k
Chunhong Hu China 24 804 0.6× 981 1.1× 749 1.0× 500 1.0× 172 0.5× 158 2.4k
Andrés Poveda Spain 39 2.2k 1.7× 2.3k 2.7× 909 1.2× 594 1.2× 86 0.2× 157 5.8k
Gang Wu China 25 982 0.7× 813 0.9× 624 0.8× 335 0.7× 352 1.0× 170 3.1k
Paola Mazzanti Italy 17 881 0.7× 886 1.0× 280 0.4× 195 0.4× 50 0.1× 70 1.7k
Kathryn A. Gold United States 29 1.8k 1.4× 2.1k 2.5× 922 1.2× 463 1.0× 201 0.6× 99 3.5k
Kamran A. Ahmed United States 29 1.5k 1.1× 1.2k 1.4× 335 0.4× 361 0.8× 433 1.2× 155 2.8k
Joseph Chao United States 29 1.6k 1.2× 2.0k 2.3× 667 0.9× 520 1.1× 186 0.5× 153 3.9k

Countries citing papers authored by Paul Mathew

Since Specialization
Citations

This map shows the geographic impact of Paul Mathew's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Mathew with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Mathew more than expected).

Fields of papers citing papers by Paul Mathew

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Mathew. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Mathew. The network helps show where Paul Mathew may publish in the future.

Co-authorship network of co-authors of Paul Mathew

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Mathew. A scholar is included among the top collaborators of Paul Mathew based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Mathew. Paul Mathew is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hwang, Clara, et al.. (2025). Dose-Dense Docetaxel and Radium-223 in Bone-Dominant Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. 23(4). 102368–102368.
2.
Silva, Verônica T. Costa e, Lesley A. Inker, George Barbério Coura-Filho, et al.. (2024). Glomerular Filtration Rate Estimation Using β2-Microglobulin and β-Trace Protein in Adults With Solid Tumors: A Prospective Cross-Sectional Study. American Journal of Kidney Diseases. 84(3). 339–348.e1. 2 indexed citations
3.
Batchala, Prem P., Paul Mathew, Linda W. Martin, et al.. (2022). CT guided injection of 99mTc-MAA for lung nodule localization prior to VATS. Clinical Imaging. 91. 97–104. 2 indexed citations
4.
Reich, Amanda J., J Reich, & Paul Mathew. (2022). Advance Care Planning, Shared Decision Making, and Serious Illness Conversations in Onconephrology. Seminars in Nephrology. 42(6). 151349–151349. 2 indexed citations
5.
Flanagan, Jane, et al.. (2020). The Last Day Narratives: An Exploration of the End of Life for Patients with Cancer from a Caregivers' Perspective. Journal of Palliative Medicine. 23(9). 1172–1176. 4 indexed citations
6.
7.
Ren, Wenying, et al.. (2016). Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition. Molecular Cancer Research. 14(12). 1176–1181. 19 indexed citations
8.
Aparicio, Ana M., Andrea Harzstark, Paul G. Corn, et al.. (2013). Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer. Clinical Cancer Research. 19(13). 3621–3630. 311 indexed citations
9.
Rosenberg, Aaron S. & Paul Mathew. (2013). Imatinib and prostate cancer: lessons learned from targeting the platelet-derived growth factor receptor. Expert Opinion on Investigational Drugs. 22(6). 787–794. 28 indexed citations
10.
Corn, Paul G., et al.. (2013). Sunitinib Plus Androgen Deprivation and Radiation Therapy for Patients With Localized High-Risk Prostate Cancer: Results From a Multi-institutional Phase 1 Study. International Journal of Radiation Oncology*Biology*Physics. 86(3). 540–545. 22 indexed citations
11.
Sheu, Tommy, Kathleen A. Bridges, Kathy A. Mason, et al.. (2012). Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer. Radiation Oncology. 7(1). 154–154. 35 indexed citations
12.
Mathew, Paul, Sijin Wen, Satoshi Morita, & Peter F. Thall. (2011). Placental Growth Factor and Soluble c-Kit Receptor Dynamics Characterize the Cytokine Signature of Imatinib in Prostate Cancer and Bone Metastases. Journal of Interferon & Cytokine Research. 31(7). 539–544. 4 indexed citations
13.
Araujo, John C., Paul Mathew, Andrew J. Armstrong, et al.. (2011). Dasatinib combined with docetaxel for castration‐resistant prostate cancer. Cancer. 118(1). 63–71. 115 indexed citations
14.
Morris, Michael J., Ethan Basch, George Wilding, et al.. (2009). Department of Defense Prostate Cancer Clinical Trials Consortium: A New Instrument for Prostate Cancer Clinical Research. Clinical Genitourinary Cancer. 7(1). 51–57. 16 indexed citations
15.
Li, Zhigang, Nora M. Navone, H. J. Yang, et al.. (2008). Androgen receptor-negative human prostate cancer cells induce osteogenesis through FGF9-mediated mechanisms. Cancer Research. 68. 1612–1612. 10 indexed citations
16.
17.
18.
Mathew, Paul, Christopher J. Logothetis, P. Dieringer, et al.. (2006). Thalidomide/Estramustine/Paclitaxel in Metastatic Androgen-Independent Prostate Cancer. Clinical Genitourinary Cancer. 5(2). 144–149. 10 indexed citations
19.
Tannir, Nizar M., Eric Jonasch, Lance C. Pagliaro, et al.. (2006). Pilot trial of bone‐targeted therapy with zoledronate, thalidomide, and interferon‐γ for metastatic renal cell carcinoma. Cancer. 107(3). 497–505. 9 indexed citations
20.
Mathew, Paul, Linda S. Elting, Catherine D. Cooksley, Steven V. Owen, & James T. Lin. (2005). Cancer in an incarcerated population. Cancer. 104(10). 2197–2204. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Teng Ma Breakdown of academic impact, for papers by Alfredo Addeo Breakdown of academic impact, for papers by Yucai Wang Breakdown of academic impact, for papers by Chunhong Hu Breakdown of academic impact, for papers by Andrés Poveda Breakdown of academic impact, for papers by Gang Wu Breakdown of academic impact, for papers by Paola Mazzanti Breakdown of academic impact, for papers by Kathryn A. Gold Breakdown of academic impact, for papers by Kamran A. Ahmed Breakdown of academic impact, for papers by Joseph Chao
Rankless by CCL
2026